Edwards Lifesciences: Q3 Earnings Insights

Shares of Edwards Lifesciences EW decreased 2.5% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 63.83% year over year to $0.51, which beat the estimate of $0.44.

Revenue of $1,141,000,000 up by 4.30% year over year, which beat the estimate of $1,080,000,000.

Guidance

Edwards Lifesciences Raises FY20 Adj. EPS Guidance From $1.75-$1.95 To $1.85-$1.95 vs $1.84 Est.

Details Of The Call

Date: Oct 21, 2020

Time: 05:00 PM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/edwds/mediaframe/40733/indexl.html

Price Action

Company's 52-week high was at $247.64

Company's 52-week low was at $66.23

Price action over last quarter: Up 7.01%

Company Profile

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.